CLDI
Calidi Biotherapeutics, Inc. (AMEX)
Healthcare — Biotechnology
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.
Price History
Fundamentals
| Market Cap | $3.05M |
| P/E Ratio (TTM) | - |
| Forward P/E | -0.18 |
| EPS (TTM) | $-4.17 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -312.39% |
| Debt/Equity | 45.74 |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | AMEX |
Technical Indicators
| RSI (14) | 44.9 |
| Beta | 1.31 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $19.20 |
| 52-Week Low | $0.12 |
| 50-Day Avg | $0.19 |
| 200-Day Avg | $0.86 |
| Avg Volume | $6.08M |
| Volume | $2.75M |
Performance Analysis
NEUTRALCLDI presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report